Suchergebnisse - (Person:"Ma, Fei")

PubPharm (55)

1

Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer : A prospective study

enthalten in: Thoracic cancer | 2024

von Wu, Y. | Mo, H. | Xu, H. | +4

2

Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy : a National Cancer Database Analysis

enthalten in: Breast cancer research and treatment | 2024

von Li, H. | Plichta, J. | Li, K. | +11

3

Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer : A phase II trial

enthalten in: Breast (Edinburgh, Scotland) | 2023

von He, M. | Liu, J. | Wang, Z. | +11

4

Efficacy of everolimus-based therapy in advanced triple-positive breast cancer : Experience from three cancer centers in China

enthalten in: Thoracic cancer | 2023

von Tan, Y. | Jiang, H. | Ma, F. | +7

5

Efficacy and safety of trastuzumab with or without a tyrosine kinase inhibitor for HER2-positive breast cancer : A systematic review and meta-analysis

enthalten in: Biochimica et biophysica acta. Reviews on cancer | 2023

von Li, L. | Zhang, D. | Wu, Y. | +2

6

Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA) : randomised, double blind, multicentre, phase 3 trial

enthalten in: BMJ (Clinical research ed.) | 2023

von Ma, F. | Yan, M. | Li, W. | +28

ErratumIn: BMJ. 2023 Nov 16;383:p2665. - PMID 37973164

7

A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2-negative metastatic breast cancer

enthalten in: Thoracic cancer | 2023

von Chai, Y. | Liu, J. | Jiang, M. | +8

8

Disparities in stage at diagnosis among breast cancer molecular subtypes in China

enthalten in: Cancer medicine | 2023

von Zeng, H. | Wu, S. | Ma, F. | +12

9

Combined chemo-endocrine therapy as a potential new option for HR+/HER2- advanced breast cancer : a prospective study of fulvestrant plus oral vinorelbine

enthalten in: Cancer biology & medicine | 2023

von Wang, X. | Yue, J. | Kang, Y. | +7

10

Multi-omics fusion analysis models with machine learning predict survival of HER2-negative metastatic breast cancer : a multicenter prospective observational study

enthalten in: Chinese medical journal | 2023

von Wang, J. | Liu, Y. | Zhang, R. | +7

1
2
3
4
5
6
Nächster »
[6]